HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Average Price Target of $14.87 According to Analysts

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $14.87.

Several equities analysts recently weighed in on HCM shares. The Goldman Sachs Group cut their price objective on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, July 23rd. HSBC raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Tuesday, September 8th. Daiwa Securities Group raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Thursday, September 3rd. Weiss Ratings cut shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Finally, Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors have recently made changes to their positions in the stock. XY Capital Ltd increased its holdings in HUTCHMED by 115.2% in the second quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock valued at $1,120,000 after purchasing an additional 55,736 shares during the last quarter. Amundi lifted its stake in HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after buying an additional 8,916 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new position in HUTCHMED in the first quarter valued at about $365,000. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Price Performance

HUTCHMED stock opened at $14.05 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64. HUTCHMED has a 1 year low of $9.77 and a 1 year high of $16.33. The company’s 50-day moving average is $13.37 and its two-hundred day moving average is $12.65.

HUTCHMED (NASDAQ:HCM) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.09). The firm had revenue of $139.14 million for the quarter, compared to the consensus estimate of $304.16 million. As a group, research analysts expect that HUTCHMED will post 0.23 earnings per share for the current year.

HUTCHMED Company Profile

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and immunological diseases. Founded in 2000, the company has built an integrated research and development platform spanning drug discovery, clinical development, regulatory activities and commercialization.

HUTCHMED’s portfolio includes targeted therapies and other treatments for solid tumors and hematologic malignancies. Its medicines include fruquintinib, marketed in China as Elunate and in the United States as Fruzaqla, and savolitinib, marketed in China as Orpathys through a collaboration with AstraZeneca.